These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 15921747)

  • 21. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
    J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range.
    Varma R; Hwang LJ; Grunden JW; Bean GW; Sultan MB
    Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis.
    Webers CA; Beckers HJ; Zeegers MP; Nuijts RM; Hendrikse F; Schouten JS
    Ophthalmology; 2010 Nov; 117(11):2067-74.e1-6. PubMed ID: 20619459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost.
    van der Valk R; Webers CA; Hendrikse F; de Vogel SC; Prins MH; Schouten JS
    Acta Ophthalmol; 2008 Jun; 86(4):415-8. PubMed ID: 18028236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
    Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
    Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
    Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
    Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
    Katz LJ; Simmons ST; Craven ER
    Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma.
    Quaranta L; Miglior S; Floriani I; Pizzolante T; Konstas AG
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4226-31. PubMed ID: 18502991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
    Zhang WY; Po AL; Dua HS; Azuara-Blanco A
    Br J Ophthalmol; 2001 Aug; 85(8):983-90. PubMed ID: 11466259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma.
    Peeters A; Webers CA; Prins MH; Zeegers MP; Hendrikse F; Schouten JS
    Acta Ophthalmol; 2010 Feb; 88(1):5-11. PubMed ID: 19432875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.